Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Antoinette R. Tan
Research Funding - Bayer
Serena Tsan-Lai Wong
No relevant relationships to disclose
Robert D. Warren
No relevant relationships to disclose
Jennifer Eng-Wong
No relevant relationships to disclose
Minetta C. Liu
No relevant relationships to disclose
Amelia Bruce Zelnak
No relevant relationships to disclose
Yong Lin
No relevant relationships to disclose
Weichung Shih
No relevant relationships to disclose
Shridar Ganesan
No relevant relationships to disclose
Generosa Grana
No relevant relationships to disclose
Claudine Isaacs
Consultant or Advisory Role - Novartis
Deborah Toppmeyer
Stock Ownership - Novartis (I)